@article{Parry_H-2022_177770,
title = {Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people},
author = {Parry, H. and Bruton, R. and Ayodele, R. and Sylla, P. and McIlroy, G. and Logan, N. and Scott, S. and Nicol, S. and Verma, K. and Stephens, C. and Willett, B. and Zuo, J. and Moss, P.},
month = {sep},
year = {2022},
abstract = {Age is the strongest determinant of COVID-19 mortality, and over 2 billion people have received primary series vaccination with BNT162b2 (mRNA) or ChAdOx1 (adenoviral vector). However, the profile of sustained vaccine immunogenicity in older people is unknown. Here, we determine spike-specific humoral and cellular immunity to 8 months following BNT162b2 or ChAdOx1 in 245 people aged 80-98 years. Vaccines are strongly immunogenic, with antibodies retained in every donor, while titers fall to 23%-26% from peak. Peak immunity develops rapidly with standard interval BNT162b2, although antibody titers are enhanced 3.7-fold with extended interval. Neutralization of ancestral variants is superior following BNT162b2, while neutralization of Omicron is broadly negative. Conversely, cellular responses are stronger following ChAdOx1 and are retained to 33%-60% of peak with all vaccines. BNT162b2 and ChAdOx1 elicit strong, but differential, sustained immunogenicity in older people. These data provide a baseline to assess optimal booster regimen in this vulnerable age group.},
volume = {3},
issue = {9},
journal = {Cell Reports Medicine},
publisher = {Elsevier},
url = {http://dx.doi.org/10.1016/j.xcrm.2022.100739},
}
